Genomic expression catalogue of a global collection of BCG vaccine strains show evidence for highly diverged metabolic and cell-wall adaptations

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Abdallah, Abdallah M ^a   Hill Cawthorne, Grant A ^a,b   Otto, Thomas D ^c   Coll, Francesc ^d   Guerra Assunção, José Afonso ^d,i   Gao, Ge ^a   Naeem, Raeece ^a   Ansari, Hifzur ^a   Malas, Tareq B ^a   Adroub, Sabir A ^a   Verboom, Theo ^e   Ummels, Roy ^e   Zhang, Huoming ^a   Panigrahi, Aswini Kumar ^a   McNerney, Ruth ^d   Brosch, Roland ^f   Clark, Taane G ^d   Behr, Marcel A ^g   Bitter, Wilbert ^e   Pain, Arnab ^a,h  

^a KING ABDULLAH UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Saudi Arabia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f INSTITUT PASTEUR   (France)

^g MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^h HOKKAIDO UNIVERSITY   (Japan)

ⁱ QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE;

ACCLIMATIZATION; BACTERIAL GENOME; CELL WALL; COPY NUMBER VARIATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PATHOGENICITY; PHYLOGENY; PROTEOMICS; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS;

ACCLIMATIZATION; BCG VACCINE; CELL WALL; DNA COPY NUMBER VARIATIONS; GENE EXPRESSION REGULATION; GENOME, BACTERIAL; HUMANS; MYCOBACTERIUM BOVIS; PHYLOGENY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEOMICS; TUBERCULOSIS;

EID: 84944930764     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep15443     Document Type: Article

References (87)

1. Frothingham, R., Hills, H. G. & Wilson, K. H. Extensive DNA sequence conservation throughout the Mycobacterium tuberculosis complex. J Clin Microbiol 32, 1639-1643 (1994).
2. Imaeda, T. Deoxyribonucleic-Acid Relatedness among Selected Strains of Mycobacterium-Tuberculosis, Mycobacterium-Bovis, Mycobacterium-Bovis Bcg, Mycobacterium-Microti, and Mycobacterium-Africanum. Int J Syst Bacteriol 35, 147-150 (1985).
3. Zwerling, A. et al. The BCG World Atlas: a database of global BCG vaccination policies and practices. PLoS medicine 8, e1001012, doi: 10.1371/journal.pmed.1001012 (2011).
4. Brewer, T. F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 31, Suppl 3, S64-67, doi: 10.1086/314072 (2000).
5. Colditz, G. A. et al. The efficacy of bacillus Calmette-Guerin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics 96, 29-35 (1995).
6. Trunz, B. B., Fine, P. & Dye, C. Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness. Lancet 367, 1173-1180, doi: 10.1016/S0140-6736(06)68507-3 (2006).
7. Mendoza-Coronel, E., Camacho-Sandoval, R., Bonifaz, L. C. & Lopez-Vidal, Y. PD-L2 induction on dendritic cells exposed to Mycobacterium avium downregulates BCG-specific T cell response. Tuberculosis (Edinb) 91, 36-46, doi: 10.1016/j.tube.2010.11.008 (2011).
8. Brandt, L. et al. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis. Infect Immun 70, 672-678 (2002).
9. Lalor, M. K. et al. Population Differences in Immune Responses to Bacille Calmette-Guerin Vaccination in Infancy. Journal of Infectious Diseases 199, 795-800, doi: 10.1086/597069 (2009).
10. Behr, M. A. BCG-different strains, different vaccines? Lancet Infect Dis 2, 86-92 (2002).
11. Aronson, J. D., Aronson, C. F. & Taylor, H. C. A twenty-year appraisal of BCG vaccination in the control of tuberculosis. A.M.A. archives of internal medicine 101, 881-893 (1958).
12. Rosenthal, S. R. et al. BCG vaccination against tuberculosis in Chicago. A twenty-year study statistically analyzed. Pediatrics 28, 622-641 (1961).
13. Liu, J., Tran, V., Leung, A. S., Alexander, D. C. & Zhu, B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Human vaccines 5, 70-78 (2009).
14. Oettinger, T., Jorgensen, M., Ladefoged, A., Haslov, K. & Andersen, P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tubercle and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease 79, 243-250, doi: 10.1054/tuld.1999.0206 (1999).
15. Behr, M. A. Correlation between BCG genomics and protective efficacy. Scand J Infect Dis 33, 249-252, doi: 10.1080/ 003655401300077180 (2001).
16. Behr, M. A. et al. Comparative genomics of BCG vaccines by whole-genome DNA microarray. Science 284, 1520-1523, doi: 10.1126/Science.284.5419.1520 (1999).
17. Brosch, R. et al. Comparative genomics uncovers large tandem chromosomal duplications in Mycobacterium bovis BCG Pasteur. Yeast 17, 111-123, doi: 10.1002/1097-0061(20000630)17:2< 111:AID-YEA17> 3.0.CO;2-G (2000).
18. Brosch, R. et al. Genome plasticity of BCG and impact on vaccine efficacy. Proceedings of the National Academy of Sciences of the United States of America 104, 5596-5601, doi: 10.1073/pnas.0700869104 (2007).
19. Mahairas, G. G., Sabo, P. J., Hickey, M. J., Singh, D. C. & Stover, C. K. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M-bovis. Journal of bacteriology 178, 1274-1282 (1996).
20. Pelayo, M. C. G. et al. A Comprehensive Survey of Single Nucleotide Polymorphisms (SNPs) across Mycobacterium bovis Strains and M. bovis BCG Vaccine Strains Refines the Genealogy and Defines a Minimal Set of SNPs That Separate Virulent M. bovis Strains and M. bovis BCG Strains. Infection and immunity 77, 2230-2238, doi: 10.1128/Iai.01099-08 (2009).
21. Behr, M. A. & Small, P. M. A historical and molecular phylogeny of BCG strains. Vaccine 17, 915-922, doi: 10.1016/S0264-410x(98)00277-1 (1999).
22. Abdallah, A. M. et al. Type VII secretion-mycobacteria show the way. Nature reviews. Microbiology 5, 883-891, doi: 10.1038/ nrmicro1773 (2007).
23. Lewis, K. N. et al. Deletion of RD1 from Mycobacterium tuberculosis mimics bacille Calmette-Guerin attenuation. J Infect Dis 187, 117-123, doi: 10.1086/345862 (2003).
24. Pym, A. S., Brodin, P., Brosch, R., Huerre, M. & Cole, S. T. Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. Mol Microbiol 46, 709-717 (2002).
25. Kozak, R. A., Alexander, D. C., Liao, R., Sherman, D. R. & Behr, M. A. Region of difference 2 contributes to virulence of Mycobacterium tuberculosis. Infection and immunity 79, 59-66, doi: 10.1128/IAI.00824-10 (2011).
26. Castillo-Rodal, A. I. et al. Mycobacterium bovis BCG substrains confer different levels of protection against Mycobacterium tuberculosis infection in a BALB/c model of progressive pulmonary tuberculosis. Infect Immun 74, 1718-1724, doi: 10.1128/ IAI.74.3.1718-1724.2006 (2006).
27. Ritz, N. et al. The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. American journal of respiratory and critical care medicine 185, 213-222, doi: 10.1164/rccm.201104-0714OC (2012).
28. Lamm, D. L. Efficacy and safety of bacille Calmette-Guerin immunotherapy in superficial bladder cancer. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 31, Suppl 3, S86-90, doi: 10.1086/314064 (2000).
29. Molife, R. & Hancock, B. W. Adjuvant therapy of malignant melanoma. Critical reviews in oncology/hematology 44, 81-102 (2002).
30. Malmstrom, P. U. et al. An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Guerin for non-muscle-invasive bladder cancer. European urology 56, 247-256, doi: 10.1016/j.eururo.2009.04.038 (2009).
31. van der Meijden, A. P. et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. European urology 44, 429-434 (2003).
32. Lukacs, S., Tschobotko, B., Szabo, N. A. & Symes, A. Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer. Case reports in urology 2013, 821526, doi: 10.1155/2013/821526 (2013).
33. Rentsch, C. A. et al. Bacillus Calmette-Guerin strain differences have an impact on clinical outcome in bladder cancer immunotherapy. European urology 66, 677-688, doi: 10.1016/j.eururo.2014.02.061 (2014).
34. Garnier, T. et al. The complete genome sequence of Mycobacterium bovis. Proceedings of the National Academy of Sciences of the United States of America 100, 7877-7882, doi: 10.1073/pnas.1130426100 (2003).
35. Coll, F. et al. PolyTB: a genomic variation map for Mycobacterium tuberculosis. Tuberculosis (Edinb) 94, 346-354, doi: 10.1016/j. tube.2014.02.005 (2014).
36. Stewart, G. R. et al. Dissection of the heat-shock response in Mycobacterium tuberculosis using mutants and microarrays. Microbiology 148, 3129-3138 (2002).
37. Stewart, G. R. et al. Overexpression of heat-shock proteins reduces survival of Mycobacterium tuberculosis in the chronic phase of infection. Nature medicine 7, 732-737, doi: 10.1038/89113 (2001).
38. Zhang, W. et al. Genome sequencing and analysis of BCG vaccine strains. Plos One 8, e71243, doi: 10.1371/journal.pone.0071243 (2013).
39. Copin, R., Coscolla, M., Efstathiadis, E., Gagneux, S. & Ernst, J. D. Impact of in vitro evolution on antigenic diversity of Mycobacterium bovis bacillus Calmette-Guerin (BCG). Vaccine 32, 5998-6004, doi: 10.1016/j.vaccine.2014.07.113 (2014).
40. Supply, P. et al. Genomic analysis of smooth tubercle bacilli provides insights into ancestry and pathoadaptation of Mycobacterium tuberculosis. Nature genetics 45, 172-179, doi: 10.1038/ng.2517 (2013).
41. Orduna, P. et al. Genomic and proteomic analyses of Mycobacterium bovis BCG Mexico 1931 reveal a diverse immunogenic repertoire against tuberculosis infection. Bmc Genomics 12, 493, doi: 10.1186/1471-2164-12-493 (2011).
42. Huard, R. C. et al. Novel genetic polymorphisms that further delineate the phylogeny of the Mycobacterium tuberculosis complex. Journal of bacteriology 188, 4271-4287, doi: 10.1128/Jb.01783-05 (2006).
43. Chen, J. M., Uplekar, S., Gordon, S. V. & Cole, S. T. A point mutation in cycA partially contributes to the D-cycloserine resistance trait of Mycobacterium bovis BCG vaccine strains. Plos One 7, e43467, doi: 10.1371/journal.pone.0043467 (2012).
44. Kolibab, K., Derrick, S. C. & Morris, S. L. Sensitivity to isoniazid of Mycobacterium bovis BCG strains and BCG disseminated disease isolates. Journal of clinical microbiology 49, 2380-2381, doi: 10.1128/JCM.00648-11 (2011).
45. Behr, M. A., Schroeder, B. G., Brinkman, J. N., Slayden, R. A. & Barry, C. E. A point mutation in the mma3 gene is responsible for impaired methoxymycolic acid production in Mycobacterium bovis BCG strains obtained after 1927. Journal of bacteriology 182, 3394-3399, doi: 10.1128/Jb.182.12.3394-3399.2000 (2000).
46. Takayama, K., Wang, L. & David, H. L. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2, 29-35 (1972).
47. Keating, L. A. et al. The pyruvate requirement of some members of the Mycobacterium tuberculosis complex is due to an inactive pyruvate kinase: implications for in vivo growth. Mol Microbiol 56, 163-174, doi: 10.1111/J.1365-2958.2005.04524.X (2005).
48. Makinoshima, H. & Glickman, M. S. Regulation of Mycobacterium tuberculosis cell envelope composition and virulence by intramembrane proteolysis. Nature 436, 406-409, doi: 10.1038/nature03713 (2005).
49. Sassetti, C. M. & Rubin, E. J. Genetic requirements for mycobacterial survival during infection. Proceedings of the National Academy of Sciences of the United States of America 100, 12989-12994, doi: 10.1073/pnas.2134250100 (2003).
50. Manganelli, R., Dubnau, E., Tyagi, S., Kramer, F. R. & Smith, I. Differential expression of 10 sigma factor genes in Mycobacterium tuberculosis. Mol Microbiol 31, 715-724 (1999).
51. Gomez, J. E. & Bishai, W. R. whmD is an essential mycobacterial gene required for proper septation and cell division. Proceedings of the National Academy of Sciences of the United States of America 97, 8554-8559, doi: 10.1073/Pnas.140225297 (2000).
52. Morris, R. P. et al. Ancestral antibiotic resistance in Mycobacterium tuberculosis. Proceedings of the National Academy of Sciences of the United States of America 102, 12200-12205, doi: 10.1073/pnas.0505446102 (2005).
53. Steyn, A. J. C. et al. Mycobacterium tuberculosis WhiB3 interacts with RpoV to affect host survival but is dispensable for in vivo growth. Proceedings of the National Academy of Sciences of the United States of America 99, 3147-3152, doi: 10.1073/Pnas.052705399 (2002).
54. Casali, N., White, A. M. & Riley, L. W. Regulation of the Mycobacterium tuberculosis mce1 operon. Journal of bacteriology 188, 441-449, doi: 10.1128/JB.188.2.441-449.2006 (2006).
55. Charlet, D. et al. Reduced expression of antigenic proteins MPB70 and MPB83 in Mycobacterium bovis BCG strains due to a start codon mutation in sigK. Molecular microbiology 56, 1302-1313 (2005).
56. Sampson, S. L. Mycobacterial PE/PPE Proteins at the Host-Pathogen Interface. Clin Dev Immunol, doi: Artn 497203, doi 10.1155/2011/497203 (2011).
57. Leung, A. S. et al. Novel genome polymorphisms in BCG vaccine strains and impact on efficacy. BMC genomics 9, 413, doi: 10.1186/1471-2164-9-413 (2008).
58. Ates, L. S. et al. Essential Role of the ESX-5 Secretion System in Outer Membrane Permeability of Pathogenic Mycobacteria. PLoS Genet 11, e1005190, doi: 10.1371/journal.pgen.1005190 (2015).
59. Lew, J. M., Kapopoulou, A., Jones, L. M. & Cole, S. T. TubercuList-10 years after. Tuberculosis (Edinb) 91, 1-7, doi: 10.1016/j. tube.2010.09.008 (2011).
60. Armitige, L. Y., Jagannath, C., Wanger, A. R. & Norris, S. J. Disruption of the genes encoding antigen 85A and antigen 85B of Mycobacterium tuberculosis H37Rv: effect on growth in culture and in macrophages. Infection and immunity 68, 767-778 (2000).
61. Heym, B. et al. Effects of overexpression of the alkyl hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium tuberculosis. Infection and immunity 65, 1395-1401 (1997).
62. Liu, K., Yu, J. & Russell, D. G. pckA-deficient Mycobacterium bovis BCG shows attenuated virulence in mice and in macrophages. Microbiology 149, 1829-1835 (2003).
63. Daffe, M. & Draper, P. The envelope layers of mycobacteria with reference to their pathogenicity. Adv Microb Physiol 39, 131-203 (1998).
64. Behr, M. A. BCG-different strains, different vaccines? The Lancet infectious diseases 2, 86-92 (2002).
65. Matsunaga, I. et al. Mycobacterium tuberculosis pks12 produces a novel polyketide presented by CD1c to T cells. The Journal of experimental medicine 200, 1559-1569, doi: 10.1084/jem.20041429 (2004).
66. Matsunaga, I., Maeda, S., Nakata, N. & Fujiwara, N. The polyketide synthase-associated multidrug tolerance in Mycobacterium intracellulare clinical isolates. Chemotherapy 58, 341-348, doi: 10.1159/000343311 (2012).
67. Av-Gay, Y., Jamil, S. & Drews, S. J. Expression and characterization of the Mycobacterium tuberculosis serine/threonine protein kinase PknB. Infection and immunity 67, 5676-5682 (1999).
68. Cole, S. T. et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393, 537-544, doi: 10.1038/31159 (1998).
69. Berthet, F. X. et al. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. Science 282, 759-762 (1998).
70. Youmans, A. S. & Youmans, G. P. Immunogenic Activity of a Ribosomal Fraction Obtained from Mycobacterium Tuberculosis. Journal of bacteriology 89, 1291-& (1965).
71. Tantimavanich, S. et al. Immunological properties of ribosomal proteins from Mycobacterium bovis BCG. Infection and immunity 61, 4005-4007 (1993).
72. Miyazaki, C. et al. Host immune responses to ribosome, ribosomal proteins, and RNA from Mycobacterium bovis bacille de Calmette-Guerin. Vaccine 17, 245-251 (1999).
73. Sinha, S. et al. Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. Microbiology 151, 2411-2419, doi: 10.1099/mic.0.27799-0 (2005).
74. Gu, S. et al. Comprehensive proteomic profiling of the membrane constituents of a Mycobacterium tuberculosis strain. Mol Cell Proteomics 2, 1284-1296, doi: 10.1074/Mcp.M300060-Mcp200 (2003).
75. Beste, D. J. V. et al. Compiling a molecular inventory for Mycobacterium bovis BCG at two growth rates: Evidence for growth rate-mediated regulation of ribosome biosynthesis and lipid metabolism. Journal of bacteriology 187, 1677-1684, doi: 10.1128/ Jb.157.5.1677-1684.2005 (2005).
76. Lewthwaite, J. C. et al. Mycobacterium tuberculosis chaperonin 60.1 is a more potent cytokine stimulator than chaperonin 60.2 (Hsp 65) and contains a CD14-binding domain. Infection and immunity 69, 7349-7355, doi: 10.1128/IAI.69.12.7349-7355.2001 (2001).
77. Bonato, V. L., Lima, V. M., Tascon, R. E., Lowrie, D. B. & Silva, C. L. Identification and characterization of protective T cells in hsp65 DNA-vaccinated and Mycobacterium tuberculosis-infected mice. Infection and immunity 66, 169-175 (1998).
78. Dubos, R. J. & Pierce, C. H. Differential characteristics in vitro and in vivo of several substrains of BCG. IV. Immunizing effectiveness. American review of tuberculosis 74, 699-717 (1956).
79. Lagranderie, M. R., Balazuc, A. M., Deriaud, E., Leclerc, C. D. & Gheorghiu, M. Comparison of immune responses of mice immunized with five different Mycobacterium bovis BCG vaccine strains. Infection and immunity 64, 1-9 (1996).
80. Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: a flexible trimmer for Illumina sequence data. Bioinformatics, doi: 10.1093/ bioinformatics/btu170 (2014).
81. Zerbino, D. R. & Birney, E. Velvet: Algorithms for de novo short read assembly using de Bruijn graphs. Genome research 18, 821-829, doi: 10.1101/Gr.074492.107 (2008).
82. Swain, M. T. et al. A post-assembly genome-improvement toolkit (PAGIT) to obtain annotated genomes from contigs. Nature protocols 7, 1260-1284, doi: 10.1038/nprot.2012.068 (2012).
83. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics 25, 1754-1760, doi: 10.1093/bioinformatics/btp324 (2009).
84. Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078-2079, doi: 10.1093/bioinformatics/ btp352 (2009).
85. Wang, J. et al. CREST maps somatic structural variation in cancer genomes with base-pair resolution. Nature methods 8, 652-654, doi: 10.1038/nmeth.1628 (2011).
86. Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome biology 11, R106, doi: 10.1186/gb-2010-11-10-r106 (2010).
87. Liu, P., Zhang, H. M., Wang, H. & Xia, Y. J. Identification of redox-sensitive cysteines in the Arabidopsis proteome using OxiTRAQ, a quantitative redox proteomics method. Proteomics 14, 750-762, doi: 10.1002/Pmic.201300307 (2014).